Everything below concerns hGH fragment. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-02-06. Numbers and descriptions here follow the published literature rather than marketing material.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
In clitoridectomy, the clitoris may be removed as part of a radical vulvectomy to treat cancer such as vulvar intraepithelial neoplasia; however, modern treatments favor more conservative approaches, as invasive surgery can have psychosexual consequences. Clitoridectomy more often involves parts of the clitoris being partially or completely removed during FGM, which may be additionally known as female circumcision or female genital cutting (FGC). Removing the glans does not mean that the whole structure is lost, since the clitoris reaches deep into the genitals. In reduction clitoroplasty, a common intersex surgery, the glans is preserved and parts of the erectile bodies are excised. Problems with this technique include loss of sensation, loss of sexual function, and sloughing of the glans. One way to preserve the clitoris with its innervations and function is to imbricate and bury the glans; however, Şenaylı et al. state that "pain during stimulus because of trapped tissue under the scarring is nearly routine. In another method, 50 percent of the ventral clitoris is removed through the level base of the clitoral shaft, and it is reported that good sensation and clitoral function are observed in follow-up"; additionally, it has "been reported that the complications are from the same as those in the older procedures for this method".
==== Negative electron-transfer dissociation ==== Fragmentation can also occur with a deprotonated species, in which an electron is transferred from the species to a cationic reagent in a negative electron transfer dissociation (NETD):
== Epidemiology == Weissenbacher-Zweymüller syndrome affects males and females in the same numbers. About 30 cases have been reported in medical literature. The disorder can be underdiagnosed causing no true frequency in the population.
== Budget principles == The U.S. Constitution (Article I, section 9, clause 7) states that "No money shall be drawn from the Treasury, but in Consequence of Appropriations made by Law; and a regular Statement and Account of Receipts and Expenditures of all public Money shall be published from time to time." Each year, the president of the United States submits a budget request to Congress for the following fiscal year as required by the Budget and Accounting Act of 1921. Current law (31 U.S.C. § 1105(a)) requires the president to submit a budget no earlier than the first Monday in January, and no later than the first Monday in February. Typically, presidents submit budgets on the first Monday in February. The budget submission has been delayed, however, in some new presidents' first year when the previous president belonged to a different party. The federal budget is calculated largely on a cash basis. That is, revenues and outlays are recognized when transactions are made. Therefore, the full long-term costs of programs such as Medicare, Social Security, and the federal portion of Medicaid are not reflected in the federal budget. By contrast, many businesses and some other national governments have adopted forms of accrual accounting, which recognizes obligations and revenues when they are incurred. The costs of some federal credit and loan programs, according to provisions of the Federal Credit Reform Act of 1990, are calculated on a net present value basis. Federal agencies cannot spend money unless funds are authorized and appropriated by law.
Sources: en.wikipedia.org
== Further reading == Bio-IT World a periodical covering glycomics Hirabayashi J, Arata Y, Kasai K (February 2001). "Glycome project: concept, strategy and preliminary application to Caenorhabditis elegans". Proteomics. 1 (2): 295–303. doi:10.1002/1615-9861(200102)1:2<295::AID-PROT295>3.0.CO;2-C. PMID 11680876. S2CID 42203562. (A proposal to base the glycome project on Caenorhabditis elegans, a microscopic worm, whose entire genome is already sequenced) 'GlycoChip' Carolyn Bertozzi's Seminar: "Chemical Glycobiology"
2 December The Gold Brush - Paint's Green Revolution, narrated by Gavin Weightman, produced by Michael Wills, directed by Jill Freeman, made by Juniper Productions 9 December Towards a Cure for Cancer, about the possibilities of hexamethylene bisacetamide (HMBA); Paul Marks and Richard Rifkind of the Memorial Sloan Kettering Cancer Center; chemist Ronald Breslow of Columbia University and HMBA; Charlotte Friend made a discovery in 1970, staining a cell with dimethyl sulfoxide (DMSO), where it made cancer cells make hemoglobin; Lorraine Baltzer, a research nurse; tretinoin was found to work in 1988, and first prescribed in September 1990; Bruce Chabner of the National Cancer Institute; differentiation therapy and Protein kinase C (PKC), signal transduction and biochemical cascades; tests on HL60 did not work; another compound was suberic bishydroxamic acid (SBHA). Narrated by Derek Cooper, directed by Karl Sabbath, made by InCA with WTTW 16 December School's Out, about developments in educational technology and the history of educational psychology, with cognitive psychologist Kristina Hooper Woolsey, educationalist Stephen Heppell, computer scientist Alan Kay, works such as the Beethoven's Ninth Symphony CD-ROM by Professor of Music at UCLA, Robert Winter; the Italian educator Maria Montessori; the Swiss child psychologist Jean Piaget; educational psychologist Jerome Bruner; computer scientist Seymour Papert.
== Applications == CyTOF provides important information at a single cell level about protein expression, immunophenotype, and functional characterization. It is a valuable tool in immunology, where the large number of parameters has helped to elucidate the workings of this complex system. For example, natural killer cells have diverse properties affected by numerous markers in various combinations, which could not be analyzed with ease prior to this technology. Simultaneously measuring many biomarkers makes it possible to identify over 30 distinct immunophenotype subsets within one complex group of cells. This can help to more fully characterize immune function, infectious disease, and cancers, and understand cells response to therapy.
=== SIRVD model === The susceptible-infected-recovered-vaccinated-deceased (SIRVD) epidemic compartment model extends the SIR model to include the effects of vaccination campaigns and time-dependent fatality rates on epidemic outbreaks. It encompasses the SIR, SIRV, SIRD, and SI models as special cases, with individual time-dependent rates governing transitions between different fractions. This model uses the following system of differential equations for the population fractions
Non-contact normothermic (or nonthermal) wound therapy, also called The Warm-Up Therapy System or wound therapy with infrared radiation, is the process of increasing the temperature of the wound bed, thereby promoting increased blood flow in the area around the wound. It is a temporary therapy (usually about 72 hours for each time usage) in which the dressing contains a special electronic warming card. The card heats to 100.4 °F (38 °C), bathing the wound in radiant heat. The closely sealed wound covering promotes a moist environment in the wound bed. It is sometimes indicated in wounds that have failed to heal with conventional therapies including wounds with compromised blood flow, diabetic ulcers, and bed sores.
Sources: en.wikipedia.org
Jollibee is a Filipino fast-food restaurant chain and the flagship brand of Jollibee Foods Corporation (JFC). Established in 1978 by Tony Tan Caktiong, it is the Philippines' top fast-food restaurant and is among the world's fastest-growing restaurant chains, having expanded its international presence almost sixfold from 2014 to 2024. As of January 2024, there were over 1,668 Jollibee fast-food restaurants, including more than 400 outside the Philippines, operating in 17 countries including Canada, Hong Kong, Macau, Malaysia, Singapore, the United Kingdom, the United States, and Vietnam, as well as across the Middle East. Jollibee is best known for its Chickenjoy fried chicken.
==== General ==== Lower Saxony has clear regional divisions that manifest themselves geographically, as well as historically and culturally. In the regions that used to be independent, especially the heartlands of the former states of Brunswick, Hanover, Oldenburg and Schaumburg-Lippe, a marked local regional awareness exists. By contrast, the areas surrounding the Hanseatic cities of Bremen and Hamburg are much more oriented towards those centres.
The source of ADP-ribose for most enzymes that perform this modification is the redox cofactor NAD+. In this transfer reaction, the N-glycosidic bond of NAD+ that bridges the ADP-ribose molecule and the nicotinamide group is cleaved, followed by nucleophilic attack by the target amino acid side chain. (ADP-ribosyl)transferases can perform two types of modifications: mono(ADP-ribosyl)ation and poly(ADP-ribosyl)ation.
The fission of one atom of uranium-235 releases 202.5 MeV (3.24×10−11 J) inside the reactor. That corresponds to 19.54 TJ/mol, or 83.14 TJ/kg. Another 8.8 MeV escapes the reactor as anti-neutrinos. When 23592U nuclei are bombarded with neutrons, one of the many fission reactions that it can undergo is the following (shown in the adjacent image):
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.